Remedy Q3 revenue triples to €39.6m following launch of Control Resonant

Remedy's third quarter revenue surged 226% following the September 24 launch of Control Resonant, a milestone game for the company. Control Resonant sold over one million units since its physical release on October 15, making it Remedy's fastest-selling title. The US accounted for nearly half of Resonant's PC and console sales, with Chinese-speaking regions and the UK ranking second and third, respectively.

On console, the UK, Canada, and Brazil led with second, third, and fourth positions. Nearly half of Resonant players were new to the Control franchise, signaling a growing audience. Remedy's outstanding wishlists total 2.4 million, offering a large potential future audience. Despite Alan Wake's quieter sales quarter, Alan Wake 2's capital expenses are fully depreciated.

Revenue for Q3 totaled €35 million, up from €6 million in the same period last year, with most revenue from game sales and royalties. Development fees from Max Payne 1 & 2 remake and Resonant's final accrual contributed €4.3 million. As Remedy now self-publishes, royalty expenses and platform fees are directly incurred and will decrease once initial investments are recouped.

Gaudechon emphasized focusing on getting Resonant into more players' hands, citing excellent reviews, market penetration, and a substantial wishlist base as solid foundations for future sales.